Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MSH6 F1088Lfs*5 MSH6 Y1256* MSH6 A1320Sfs*5 |
| Therapy | Nivolumab |
| Indication/Tumor Type | colorectal carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MSH6 F1088Lfs*5 MSH6 Y1256* MSH6 A1320Sfs*5 | colorectal carcinoma | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a clinical case study, Opdivo (nivolumab) treatment resulted in stable disease lasting four months in a colorectal carcinoma patient harboring MSH6 F1088Lfs*5, Y1256*, and A1320Sfs*5 (PMID: 35739269). | 35739269 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35739269) | Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. | Full reference... |